Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Completed 4

Sponsor Class

OTHER 4NETWORK 3NIH 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Neoplasm Metastasis 1Metabolic Syndrome 1Hypogonadism 1Fatty Liver 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Interventional × Orchiectomy × Clear all
NCT02058706 2023-05-10

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
71 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

NCT00104715 2021-02-21

Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer

UNICANCER

Phase 3 Completed
385 enrolled
Genitourinary

Prostatic Neoplasms

NCT00081159 2016-11-10

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

M.D. Anderson Cancer Center

Phase 2 Completed
80 enrolled 6 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02102646 2015-10-28

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

Herlev Hospital

Phase 4 Completed
31 enrolled
Genitourinary

Fatty Liver, Hypogonadism, Prostatic Neoplasms, Metabolic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡